study to assess the safety, tolerability, and pharmacokinetics of AMP-224 in patients with advanced cancer

Exclusion Criteria

• - Prior cancer therapies must have completed at least 14 days or 5 half-lives (whichever is longer) prior to first dose of AMP-224
• - Prior treatment with an anti-PD1 antibody therapy
• - Known antibody response against prior antibody therapy or fusion protein therapeutics
• - Major surgery within 4 weeks prior to first dose of AMP-224
• - Prior allogeneic or autologous bone marrow or organ transplantation
• - Known and/or a history or evidence of autoimmune disease except vitiligo, resolved childhood asthma and stable hypothyroidism
• - Received an immunomodulatory drug within 2 weeks of first dose of AMP-224
• - Active infections requiring antibiotics, physician monitoring, or recurrent fevers >100.4 degrees fahrenheit associated with a clinical diagnosis of active infection
• - Patients with cirrhosis
• - Clinically significant cardiac or electrocardiogram abnormalities
• - History or evidence of HIV
• - Active viral disease (except when the viral infection is associated with the malignancy)
• - Regular use of illicit drugs or a recent history of substance abuse
• - Pregnant or breastfeeding women